Life Science Innovation
Committed to driving the transformation of biotechnology
and empowering the development of innovative enterprises

Learn more

Investment in Life Science

With Global Horizon, Chinese Angle strategy, BOCG strives to support true innovation and disruptive technology of life science.

Learn More

One Team, Global Reach

Accumulated 100+ years’ experience and US$ 1+ billion proven record, the BOCG veteran team builds its office and franchise in Shenzhen, Shanghai, Hong Kong, and Gothenburg of Sweden,  and extensive networks and footprint in Greater China, Asia, USA and Europe.

Learn More

ESG Empowerment

A signatory to the UN PRI and committed to promoting sustainable development and impact investment.

Learn More

Latest News

BOCG Insights | BOCG’s CEO Frank Yang Invited to Lecture on Biopharmaceutical Investment and Financing in Hong Kong
Jul 18, 2024

On July 12, 2024, Mr. Frank Yang, founding partner & CEO of Blue Ocean Capital Group, was invited by the HK Bio-Med Innotech Association and the Hong Kong Productivity Council to lecture in Hong Kong for entrepreneurs, scientists, and managers in the biopharmaceutical industry.

BOCG's Family | Innorna Announces U.S. FDA Rare Pediatric Disease Designation Granted to IN022 for the Treatment of Homocystinuria
Jul 9, 2024

BOCG's portfolio company Innorna has been granted the U.S. FDA Rare Pediatric Disease Designation (RPDD) for IN022, their investigational therapy for treating classic homocystinuria (HCU).

BOCG named a Top 10 Impact Investment Institution in 2023
Apr 18, 2024

China’s Best Impact Investments of the Year Awards were solemnly announced, with BOCG winning the “2023 For Good Award | Top 10 Impact Investment Institution”. Dr. Yanling Wen, Chief Medical Officer of BOCG, was invited to participate in a roundtable forum to discuss the challenges and opportunities of ESG impact investment in China.